S
Sandra H. Thomas
Researcher at City of Hope National Medical Center
Publications - 59
Citations - 2101
Sandra H. Thomas is an academic researcher from City of Hope National Medical Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 24, co-authored 55 publications receiving 1681 citations.
Papers
More filters
Journal ArticleDOI
Phase 1 studies of central memory–derived CD19 CAR T–cell therapy following autologous HSCT in patients with B-cell NHL
Xiuli Wang,Leslie Popplewell,Jamie Wagner,Araceli Naranjo,M. Suzette Blanchard,Michelle Mott,Adam Norris,Ching Lam W Wong,Ryan Urak,Wen-Chung Chang,Samer K. Khaled,Tanya Siddiqi,Lihua E. Budde,Jingying Xu,Brenda Chang,Nikita Gidwaney,Sandra H. Thomas,Laurence J.N. Cooper,Stanley R. Riddell,Christine E. Brown,Michael C. Jensen,Stephen J. Forman +21 more
TL;DR: Data from 2 safety/feasibility studies demonstrating the safety and feasibility of CD19 CAR TCM therapy after HSCT are presented, investigating different T-cell populations and CAR constructs.
Journal ArticleDOI
CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin
Robert T. Chen,Jessie Hou,Edward M. Newman,Young L. Kim,Cecile A. Donohue,Xueli Liu,Sandra H. Thomas,Stephen J. Forman,Susan E. Kane +8 more
TL;DR: MMAE resistance and MDR1 expression are possible modes of BV resistance for Hodgkin lymphoma both in vitro and in patients.
Journal ArticleDOI
Lenalidomide enhances the function of CS1 chimeric antigen receptor redirected T cells against multiple myeloma
Xiuli Wang,Miriam Walter,Ryan Urak,Lihong Weng,Christian Huynh,Laura Lim,ChingLam W. Wong,Wen-Chung Chang,Sandra H. Thomas,James F. Sanchez,Lu Yang,Christine E. Brown,Flavia Pichiorri,Myo Htut,Amrita Krishnan,Stephen J. Forman +15 more
TL;DR: It is demonstrated that lenalidomide improves the anti-multiple myeloma properties of CS1-directed CAR T cells and provides a basis for a planned clinical trial using the combination of lenalidOMide with engineered T cells against CS1 in relapsed myelomas.
Journal ArticleDOI
Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma
Robert T. Chen,Joycelynne Palmer,Sandra H. Thomas,Ni Chun Tsai,Len Farol,Auayporn Nademanee,Stephen J. Forman,Ajay K. Gopal +7 more
TL;DR: Brentuximab vedotin before reduced- intensity allo-HCT does not appear to adversely affect engraftment, GVHD, or survival and may provide sufficient disease control to enable reduced-intensity allo -HCT.
Journal ArticleDOI
Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma
Robert T. Chen,Joycelynne Palmer,Peter Martin,Nicole Tsai,Young L. Kim,Bihong T. Chen,Leslie Popplewell,Tanya Siddiqi,Sandra H. Thomas,Michelle Mott,Firoozeh Sahebi,Saro H. Armenian,John P. Leonard,Auayporn Nademanee,Stephen J. Forman +14 more
TL;DR: Brentuximab vedotin as second-line therapy is active, well tolerated, and allows adequate stem cell collection and engraftment in patients with relapsed or refractory Hodgkin lymphoma.